Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
AssigneeTilt Biotherapeutics Oy
InventorsAkseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
Life of this patent
Estimating the term…
Abstract
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
Claims27
An oncolytic adenoviral vector comprising:
- deletion of a nucleic acid sequence in the E3 region, and
- a nucleic acid sequence encoding a bispecific monoclonal antibody in the place of the deleted nucleic acid sequence in E3 region, wherein the bispecific monoclonal antibody comprises a single chain variable fragment (scFv) specific for a cell surface molecule and a scFv specific for a tumor antigen.
A pharmaceutical composition comprising an oncolytic adenoviral vector, wherein the oncolytic adenoviral vector comprises:
- a deletion of a nucleic acid sequence in the E3 region, and
- a nucleic acid sequence encoding a bispecific monoclonal antibody in the place of the deleted nucleic acid sequence in E3 region, wherein the bispecific monoclonal antibody comprises a single chain variable fragment (scFv) specific for a cell surface molecule and a scFv specific for a tumor antigen.
(canceled)
(canceled)
A method of treating cancer in a subject, wherein the method comprises administration of an oncolytic adenoviral vector to a subject, wherein the oncolytic adenoviral vector comprises:
- a deletion of a nucleic acid sequence in the E3 region, and
- a nucleic acid sequence encoding a bispecific monoclonal antibody in the place of the deleted nucleic acid sequence in E3 region, wherein the bispecific monoclonal antibody comprises a single chain variable fragment (scFv) specific for a cell surface molecule and a scFv specific for a tumor antigen.
(canceled)
Dependencies are inferred from the claim text.